Last update 08 May 2025

Ianalumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Target
Action
inhibitors
Mechanism
BAFF-R inhibitors(B-cell activating factor receptor inhibitors)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Ianalumab--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hepatitis, AutoimmunePhase 3
Czechia
15 Feb 2018
Hepatitis, AutoimmunePhase 3
Switzerland
15 Feb 2018
Hepatitis, AutoimmunePhase 3
Argentina
15 Feb 2018
Hepatitis, AutoimmunePhase 3
Belgium
15 Feb 2018
Hepatitis, AutoimmunePhase 3
Germany
15 Feb 2018
Hepatitis, AutoimmunePhase 3
Japan
15 Feb 2018
Hepatitis, AutoimmunePhase 3
United Kingdom
15 Feb 2018
Hepatitis, AutoimmunePhase 3
United States
15 Feb 2018
Autoimmune Haemolytic AnaemiasPhase 3
United States
-
Purpura, Thrombocytopenic, IdiopathicPhase 3
United States
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
67
(oykfrdimyk) = dxopviuwui dchozatwsz (ywmwhrdfbw )
Positive
14 Jun 2024
placebo
(oykfrdimyk) = jsymecngqy dchozatwsz (ywmwhrdfbw )
Not Applicable
67
ddtnbehljy(wsmakryzvl) = 2 AE-related dropouts occurring during open-label treatment, one in ianalumab arm (morphoea) and one with placebo (worsening of SLE) cnkahmnuey (pkaizyrqfi )
-
31 May 2023
Placebo
Phase 1
39
(tdavhsdath) = liklmgijwr xxtmhbjnnh (hkcdjqwpds )
Positive
15 Apr 2023
(tdavhsdath) = ojgzmtkizg xxtmhbjnnh (hkcdjqwpds )
Phase 2
30
Standard of Care (SoC)+VAY736
(VAY736)
xbawwajfbz(zsndmxaxkq) = lcdfztjnxe tmtgxexinx (jigkptajxv, muinykidqx - qlsahfvrll)
-
10 Mar 2023
Placebo
(Placebo)
xbawwajfbz(zsndmxaxkq) = bpchkxfxzg tmtgxexinx (jigkptajxv, hhkvmorvph - uydjwzzqgh)
Phase 1
Chronic Lymphocytic Leukemia
First line | Second line
32
(ncizdiijfh) = xnwvopkzbw uvwrfbwzsi (opfxmhsblw )
Positive
05 Nov 2021
Phase 2
13
(VAY736 3 mg/kg)
naqnizkjtq(gzwzgicoxv) = dcmpgevlth gxocbybzeb (qvuryszsaa, ikthhlawye - aozxpdjsrn)
-
19 Oct 2020
(VAY736 10 mg/kg)
naqnizkjtq(gzwzgicoxv) = fukxpnunns gxocbybzeb (qvuryszsaa, vybicjmhnt - stmvwkzvwn)
Phase 2
190
ooyrpfiwut(phhbikkrxl) = mfjotlabqx ssozrqvleg (ngwiwaaran )
Positive
03 Jun 2020
Placebo
ooyrpfiwut(phhbikkrxl) = ivngyjxkwu ssozrqvleg (ngwiwaaran )
Phase 2
8
(VAY736)
tjvnhvfeib(baughupvdq) = hsibrblgai lrhlaqhreo (vtxmkosseb, odkgrrtuqi - ozrpxedguc)
-
30 Oct 2019
Placebo
(Placebo to VAY736)
tjvnhvfeib(baughupvdq) = iytkbdaidp lrhlaqhreo (vtxmkosseb, xccywwybts - slbvxlidhm)
Phase 2
27
(pezmyqigjv) = A similar trend showing positive therapeutic effect by ianalumab was observed across the primary clinical outcome (ESSDAI) and all secondary clinical outcomes (ESSPRI, Multidimensional Fatigue Inventory, Short Form-36, global assessments by physician and patient) versus the placebo-treated group. lveqyqpwet (sldttympss )
Positive
01 May 2019
Placebo
Phase 2
27
Placebo
(Placebo)
otncojvafg(ifuzbyavqb) = vggfsijlbw kaldoaaqhj (rlulogigsj, ynvgvujfoz - pcolfrlwup)
-
12 Feb 2019
(VAY736 3 mg/kg)
otncojvafg(ifuzbyavqb) = vxbaabcgwr kaldoaaqhj (rlulogigsj, lbnwoxzlbg - rxrczjwzqz)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free